Redcare Pharmacy's Margin Milestone Fails to Shield Shares From Post-Earnings Selloff
Published on 08/02/2026 at 16:24 | Redaktion boerse-global.de
The arithmetic of the second quarter looked close to flawless. A ten-year high in profitability, a 63 percent jump in adjusted EBITDA, and a guidance raise that management felt confident enough to reaffirm. Yet when the closing bell rang on Friday, Redcare Pharmacy shares had shed 5.49 percent to settle at EUR 61.95 — a stark reminder that in the current market, good news is often just a cue to take profits.
The disconnect between the operating numbers and the share price reaction has left investors weighing two competing narratives: one rooted in the strength of the underlying business, the other in the market's refusal to pay up for expectations that were already running hot.
A Decade-Best Margin Arrives Ahead of Schedule
The headline figure from the July earnings release was the adjusted EBITDA margin of 3.5 percent — the strongest quarterly showing in ten years for the online pharmacy. Adjusted EBITDA came in at EUR 29.6 million, comfortably ahead of the roughly EUR 23.5 million analysts had penciled in. Group revenue advanced 20 percent in the quarter to EUR 853 million, bringing the first-half total to EUR 1.7 billion.
Management credited the margin expansion to improved operating leverage and a more efficient marketing mix. There was also a notable first: the international segment delivered a positive adjusted EBITDA for the first time, marking a milestone for the business outside Redcare's core markets.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
The numbers were strong enough that several major banks moved quickly to revise their price targets — though the revisions tell a more nuanced story than the headline upgrades suggest. UBS's Olivier Calvet lifted his target from EUR 60 to EUR 74 while keeping a "Neutral" stance, flagging that the pace of acceleration in the German prescription business had not matched the first quarter's momentum. Deutsche Bank's Jan Koch was more effusive, raising his target from EUR 102 to EUR 103 with a "Buy" rating intact and describing the quarter as "outstanding." Warburg Research remains the most bullish house on the street with a EUR 116 target.
The Rx Engine Keeps Humming, Just Not Fast Enough
The core growth driver remains the German prescription segment, where revenue jumped 58 percent year-on-year in the second quarter. The nationwide rollout of digital health infrastructure has been a tailwind, and Redcare's "CardLink" technology has allowed the company to capture a larger share of the prescription market through a seamless digital redemption process.
Active customers reached 14.7 million by the end of June, up 1.2 million from a year earlier. The e-prescription Net Promoter Score of 77 suggests that users migrating to the platform through the digital prescription transition are sticking around.
Yet it was precisely this segment that triggered Friday's selloff. Some market participants had positioned for an even stronger surge in German Rx growth as the digital infrastructure rollout progresses. The 58 percent expansion, while impressive in absolute terms, fell short of the most aggressive expectations. The pattern is a textbook "sell the news" reaction: strong results, but not strong enough to justify the premium that had built up in the share price.
Guidance Holds, But Seasonality Looms
Management reaffirmed its raised full-year 2026 outlook: revenue growth of 15 to 17 percent with an adjusted EBITDA margin between 2.5 and 3.0 percent. With a quarterly margin already at 3.5 percent, the company appears well positioned to hit those targets — assuming the second half doesn't deliver a pronounced seasonal downturn. The third quarter is traditionally the weakest period for the pharmacy sector.
Redcare Pharmacy at a turning point? This analysis reveals what investors need to know now.
Consensus estimates have shifted accordingly. Analysts now see full-year 2026 revenue of approximately EUR 3.41 billion, while the expected net loss per share has been trimmed from EUR 0.72 to roughly EUR 0.60. The average analyst price target stands near EUR 86, well above the current trading level.
Chart Levels in Focus
From a technical standpoint, the stock closed just above its 50-day moving average of EUR 60.68, while remaining 8.26 percent above its 200-day average of EUR 57.23 — a level chart technicians view as a critical support line for the long-term uptrend established this summer. The Relative Strength Index sits at 43.2, indicating a neutral posture rather than an oversold condition, despite a nearly 11 percent decline over the past 30 days.
The coming sessions will determine whether the operational strength or the market's skepticism ultimately prevails. For now, the stock finds itself in an unusual position: backed by the strongest fundamentals in a decade, yet struggling to convince traders that the growth story hasn't already been priced in.
Ad
Redcare Pharmacy Stock: New Analysis - 2 August
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
